The weight-loss drugs are linked with reduced rates of excess drinking and opioid overdoses, suggesting they may tamp down substance use cravings too.

Drugs such as Novo Nordisk’s Ozempic can cut drug and alcohol abuse by up to 50%, a study found, adding to mounting evidence that the drugs yield health benefits beyond diabetes and weight loss.

Weight-loss drugs such as Ozempic, made by Denmark’s Novo Nordisk, can reduce rates of opioid and alcohol abuse by up to 50%, according to a new study that supports expectations the drugs can offer greater benefits than just weight and diabetes management.

Diet and diabetes drugs like Ozempic and Mounjaro could also help people struggling with alcohol and opioid abuse, according to a new study.

Beyond semaglutide, participants in the latest study were using drugs including Eli Lilly’s weight loss and diabetes drug tirzepatide, the active ingredient in Mounjaro, and Novo Nordisk’s liraglutide, which is sold under the brand names Victoza and Saxenda to treat both diabetes and obesity.

Weight loss medications such as Ozempic may be able to cut drug and alcohol abuse in half, according to a new study from the scientific journal Addiction. The research, published Thursday, found

Drugs​ like Mounjaro and Ozempic, which many use for weight loss,​​ may also help patients suffering from addiction, according to a new study.

Researchers analyzed 1.3 million health records and found Ozempic, Mounjaro could lower rates of drug and alcohol overdoses.

A new study has found that drugs like Ozempic, which were originally designed for people with type 2 diabetes before gaining popularity for weight loss, could treat alcohol addiction too. Around 2.6 million deaths per year are attributable to alcohol consumption,